Eylea Hd Drug Information
Generic name: AFLIBERCEPT
Vascular Endothelial Growth Factor Inhibitor [EPC]
Uses of Eylea Hd
Neovascular (Wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3
Diabetic Retinopathy (DR)
Dosage & Administration of Eylea Hd
Side Effects of Eylea Hd
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice. A total of 1755 patients were treated with EYLEA HD and 804 patients were treated with EYLEA 2 mg in three clinical studies. The most common adverse reactions reported in ≥3% of patients treated with EYLEA HD were cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment and vitreous floaters.
Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) The data described below reflect exposure to EYLEA HD administered every 12 weeks (HDq12), EYLEA HD administered every 16 weeks (HDq16), or EYLEA 2 mg administered every 8 weeks (2q8) in controlled clinical studies (PULSAR and PHOTON), each for 96 weeks. Table 1: Adverse Reactions (≥1%) in at least one group in the PULSAR or PHOTON studies Adverse Reactions PULSAR PHOTON EYLEA HDq12 EYLEA HDq16 EYLEA 2q8 EYLEA HDq12 EYLEA HDq16 EYLEA 2q8 n=335 n=338 n=336 n=328 n=163 n=167 Cataract Represents grouping of related terms 10% 10% 10% 10% 13% 7% Vision blurred 9% 9% 8% 5% 4% 6% Intraocular pressure increased 5% 4% 3% 4% 1% 5% Conjunctival hemorrhage 3% 3% 3% 5% 5% 4% Ocular discomfort/eye pain/eye irritation 3% 4% 4% 5% 4% 4% Vitreous floaters 2% 6% 5% 6% 4% 4% Vitreous detachment 2% 4% 2% 5% 3% 4% Corneal epithelium defect 3% 3% 4% 4% 9% 2% Retinal hemorrhage 5% 6% 6% 0 4% 1% Dry eye 3% 3% 5% 2% 4% 2% Intraocular inflammation 2% 1% 2% 2% 1% 1% Retinal pigment epithelial tear/epitheliopathy 2% 2% 2% 1% 0 0 Vitreous hemorrhage <1% 1% 1% 2% 3% 2% Retinal Detachment 1% 1% <1% <1% 1% 0 Foreign body sensation in eyes 1% 2% 2% <1% 1% 0 Ocular hyperemia 1% <1% 1% <1% 0 0 Retinal pigment epithelial detachment 1% 1% 3% 0 0 0 Adverse drug reactions (ADRs) reported in <1% of participants treated with EYLEA HD were lacrimation increased, eyelid edema, hypersensitivity (includes adverse events of rash, urticaria, pruritus), and injection site hemorrhage. Macular Edema Following Retinal Vein Occlusion (RVO) The data described below reflects 36 weeks exposure to EYLEA HD administered every 8 weeks (HDq8) after 3 or 5 initial monthly doses (HDq4), or EYLEA 2 mg administered every 4 weeks (2q4) in a controlled clinical study (QUASAR). . Table 2: Most Common Adverse Reactions (≥1%) in at least one group in the QUASAR study Adverse Reactions EYLEA HDq8 following 3 initial doses (HDq4) (N=293) EYLEA HDq8 following 5 initial doses (HDq4) (N=298) EYLEA 2q4 (N=301) Intraocular pressure increased Represents grouping of related terms 7% 6% 3% Vision blurred 5% 3% 2% Conjunctival hemorrhage 3% 2% 2% Ocular discomfort/eye pain/eye irritation 3% 3% 1% Vitreous detachment 3% 3% 1% Cataract 2% 4% 3% Corneal epithelium defect 2% 2% 2% Dry eye 2% 2% 2% Vitreous floaters 1% 1% 1% Intraocular inflammation 1% <1% 1% Vitreous hemorrhage 1% 1% 0 Hypersensitivity Represents reported non-ocular adverse events of hypersensitivity, rash, urticaria and pruritus 1% 1% 1% Adverse reactions reported in <1% of the patients treated with EYLEA HD in the RVO study were foreign body sensation in eyes (includes foreign body sensation in eyes and sensation of foreign body), ocular hyperaemia (includes conjunctival hyperemia, conjunctival irritation, ocular hyperemia), retinal hemorrhage, retinal pigment epithelial detachment (includes detachment of retinal pigment epithelium), retinal pigment epithelial tear/epitheliopathy (includes retinal pigment epitheliopathy), and retinal tear.
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of aflibercept. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye disorders : Retinal vasculitis and occlusive retinal vasculitis related to intravitreal injection with aflibercept (reported at a rate of 0.6 and 0.2 per 1 million injections, respectively, based on postmarketing experience from November 2011 until November 2023). Scleritis.
Warnings & Cautions for Eylea Hd
Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion Intravitreal injections
including those with aflibercept have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion . Proper aseptic injection technique must always be used when administering EYLEA HD. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
Increase in Intraocular Pressure Acute increases in intraocular pressure have been seen
within 60 minutes of intravitreal injection, including with EYLEA HD. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with vascular endothelial growth factor (VEGF) inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
Thromboembolic Events
There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 96 was 1.8% (12 out of 673) in the combined group of patients treated with EYLEA HD compared with 3.3% (11 out of 336) in patients treated with EYLEA 2 mg. The incidence of reported thromboembolic events in the DME study (PHOTON) from baseline to week 96 was 6.7% (33 out of 491) in the combined group of patients treated with EYLEA HD compared with 7.2% (12 out of 167) in patients treated with EYLEA 2 mg. The incidence of reported thromboembolic events in the RVO study (QUASAR) from baseline to week 36 was 0.5% (3 out of 591) in the combined group of patients treated with EYLEA HD compared with 1.7% (5 out of 301) in patients treated with EYLEA 2 mg.
Pregnancy Safety for Eylea Hd
Pregnancy Risk Summary Adequate and well-controlled studies with EYLEA HD have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. A fetal No Observed Adverse Effect Level (NOAEL) was not identified.
At the lowest dose shown to produce adverse embryofetal effects, systemic exposure (based on AUC for free aflibercept) was approximately 0.9 -fold of the population pharmacokinetic estimated exposure in humans after an intravitreal dose of 8 mg (see Data ). Animal reproduction studies are not always predictive of human response, and it is not known whether EYLEA HD can cause fetal harm when administered to a pregnant woman. Based on the anti-VEGF mechanism of action for aflibercept , treatment with EYLEA HD may pose a risk to human embryofetal development. EYLEA HD should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data Animal Data In two embryofetal development studies, aflibercept produced adverse embryofetal effects when administered every three days during organogenesis to pregnant rabbits at intravenous doses ≥3 mg per kg, or every six days during organogenesis at subcutaneous doses ≥0.1 mg per kg. Adverse embryofetal effects included increased incidences of postimplantation loss and fetal malformations, including anasarca, umbilical hernia, diaphragmatic hernia, gastroschisis, cleft palate, ectrodactyly, intestinal atresia, spina bifida, encephalomeningocele, heart and major vessel defects, and skeletal malformations (fused vertebrae, sternebrae, and ribs; supernumerary vertebral arches and ribs; and incomplete ossification). The maternal No Observed Adverse Effect Level (NOAEL) in these studies was 3 mg per kg. Aflibercept produced fetal malformations at all doses assessed in rabbits and the fetal NOAEL was not identified.
At the lowest dose shown to produce adverse embryofetal effects in rabbits (0.1 mg per kg), systemic exposure (AUC) of free aflibercept was approximately 0.9-fold of the population pharmacokinetic estimated systemic exposure (AUC) in humans after an intravitreal dose of 8 mg.
Pediatric Use of Eylea Hd
Pediatric Use The safety and effectiveness of EYLEA HD in pediatric patients have not been established.
Contraindications for Eylea Hd
Ocular or Periocular Infections
EYLEA HD is contraindicated in patients with ocular or periocular infections.
Active Intraocular Inflammation
EYLEA HD is contraindicated in patients with active intraocular inflammation.
Hypersensitivity
EYLEA HD is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in EYLEA HD. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.
Overdosage Information for Eylea Hd
Overdosing with increased injection volume may increase intraocular pressure. Therefore, in case of overdosage, intraocular pressure should be monitored and if deemed necessary by the treating physician, adequate treatment should be initiated.
Clinical Studies of Eylea Hd
Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
The safety and efficacy of EYLEA HD were assessed in a randomized, multi-center, double-masked, active-controlled study (PULSAR) in treatment-naïve patients with nAMD. A total of 1009 patients were treated and analyzed for efficacy (673 with EYLEA HD). Patients were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: 1) EYLEA HD administered every 12 weeks following 3 initial monthly doses (HDq12); 2) EYLEA HD administered every 16 weeks following 3 initial monthly doses (HDq16); 3) EYLEA 2 mg administered every 8 weeks (2q8) following 3 initial monthly doses. In the EYLEA HD groups, patients could be treated as frequently as every 8 weeks based on protocol-defined visual and anatomic criteria, starting at week 16. Starting at week 52, patient dosing intervals could be extended by 4-week increments if all protocol-defined visual and anatomic criteria were met at visits in Year 2 (i.e., BCVA loss <5 letters from Week 12, no fluid in the central subfield on OCT, and no new onset foveal hemorrhage or foveal neovascularization). Patients ranged from 50 to 96 years of age with a mean of 74.5 years. At baseline, mean visual acuity was approximately 60 letters (range: 24 to 78 letters). The primary efficacy endpoint was the change from baseline in BCVA at week 48 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
Both HDq12 and HDq16 treatments were shown to be non-inferior and clinically equivalent to 2q8 treatment with respect to the change in BCVA score at week 48 using the pre-specified non-inferiority margin of 4 letters. 6.2% of total EYLEA HD treated patients who met protocol-defined criteria to be treated every 8 weeks did not maintain a response with every 8 weeks dosing after successful response to the 3 initial monthly doses. In patients completing week 48, the mean number of injections administered was 5.2 in the HDq16 group (n=312), 6.1 in the HDq12 group (n=316) and 6.9 in the EYLEA q8 group (n=309). The treatment effect with EYLEA HD in mean change in BCVA was maintained through week 96. During the second year of treatment in patients who completed week 96, the mean number of injections administered was 3 in the HDq16 group (n=292), 3.7 in the HDq12 group (n=291) and 5.8 in the 2q8 group (n=286). In the pooled HDq12 and HDq16 groups, patients maintained their visual and anatomic outcomes through week 96, with 71% and 46.8% of patients attaining treatment intervals of ≥16 weeks and ≥20 weeks, respectively, at week 96. Detailed results from the analysis of the PULSAR study are shown in Table 3 and Figure 8 below. Efficacy results in all subgroups (e.g., age, gender, geographic region, ethnicity, race, baseline BCVA and lesion type) were consistent with those in the overall population.
Table 3: Efficacy Outcomes at Weeks 48 and 96 (Full Analysis Set) in PULSAR Study Efficacy Outcomes EYLEA HDq12 EYLEA HDq16 EYLEA 2q8 BCVA = Best Corrected Visual Acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; SD = Standard Deviation; LS = Least Square; SE = Standard Error; CI = Confidence Interval; MMRM = Mixed Model for Repeated Measurements Full Analysis Set Full Analysis Set (FAS) includes all randomized patients who received at least 1 dose of study medication N=335 N=338 N=336 Efficacy Outcomes at Week 48 Mean change in BCVA as measured by ETDRS letter score from baseline (SD) Observed values at week 48: n=299 for HDq12; n=289 for HDq16; n=285 for 2q8 6.7 6.2
LS mean (SE) change from baseline Estimate based on the
MMRM model, was computed for the differences of HDq12 minus 2q8 and HDq16 minus 2q8, respectively, with two-sided 95% CIs 6.1 5.9
Difference in LS mean (95% CI) -1.0 (-2.9, 0.9) -1.1 (-3.0, 0.7)
Efficacy Outcomes at Week 96 Mean change in BCVA as measured by ETDRS letter score from baseline (SD) Observed values at week 96: n=256 for HDq12; n=264 for HDq16; n=243 for 2q8 5.9 5.6
LS mean (SE) change from baseline 5.6 5.5 6.6 Difference in LS
mean (95% CI), A non-inferiority margin was not available for week 96 -1.0 (-2.8, 0.8) -1.1 (-2.9, 0.7) Figure 8: Mean Change from Baseline in BCVA as measured by ETDRS Letter Score by Visits through Week 96 (Observed Cases) Figure 8
Diabetic Macular Edema (DME)
The safety and efficacy of EYLEA HD was assessed in a randomized, multi-center, double-masked, active-controlled study (PHOTON) in patients with DME involving the center of the macula. A total of 658 patients were treated and analyzed for efficacy (491 with EYLEA HD). Patients were randomly assigned in a 2:1:1 ratio to 1 of 3 treatment groups: 1) EYLEA HD administered every 12 weeks following 3 initial monthly doses (HDq12); 2) EYLEA HD administered every 16 weeks following 3 initial monthly doses (HDq16); 3) EYLEA 2 mg administered every 8 weeks (2q8) following 5 initial monthly doses. In the EYLEA HD groups, patients could be treated as frequently as every 8 weeks based on protocol-defined visual and anatomic criteria, starting at week 16. Starting at week 52, patient dosing intervals could be extended by 4-week increments if all protocol-defined visual and anatomic criteria were met at visits in Year 2 (i.e., <5 letter loss in BCVA from week 12, and CRT <300 μm on OCT). Patient ages ranged from 24 to 90 years with a mean of 62.3 years.
A total of 44% of patients were previously treated for DME. At baseline, the overall mean visual acuity was 63 letters (range: 24 to 79 letters). The primary efficacy endpoint was the change from baseline in BCVA at week 48 as measured by the ETDRS letter score. Both HDq12 and HDq16 treatments were shown to be non-inferior and clinically equivalent to 2q8 treatment with respect to the change in BCVA score at week 48 using the pre-specified non-inferiority margin of 4 letters. 1.5% of total EYLEA HD treated patients who met protocol-defined criteria to be treated every 8 weeks did not maintain a response with every 8 weeks dosing after successful response to the 3 initial monthly doses. In patients completing week 48, the mean number of injections administered was 5 in the HDq16 group (n=156), 6 in the HDq12 group (n=300) and 7.9 in the EYLEA q8 group (n=157). The treatment effect with EYLEA HD in mean change in BCVA was maintained through week 96. During the second year of treatment, in patients completing week 96, the mean number of injections administered was 2.8 in the HDq16 group (n=139), 3.5 in the HDq12 group (n=256) and 5.9 in the 2q8 group (n=139). In the pooled HDq12 and HDq16 groups, patients maintained their visual and anatomic outcomes through week 96, with 72.4% and 44.3% of patients attaining treatment intervals of ≥16 weeks and ≥20 weeks, respectively at week 96. Detailed results from the analysis of the PHOTON study are shown in Table 4 and Figure 9 below.
Table 4: Efficacy Outcomes at Weeks 48 and 96 (Full Analysis Set) in PHOTON Study Efficacy Outcomes EYLEA HDq12 EYLEA HDq16 EYLEA 2q8 BCVA = Best Corrected Visual Acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; SD = Standard Deviation; LS = Least Square; SE = Standard Error; CI = Confidence Interval; MMRM = Mixed Model for Repeated Measurements. Full Analysis Set FAS includes all randomized patients who received at least 1 dose of study medication N=328 N=163 N=167 Efficacy Outcomes at Week 48 Mean change in BCVA as measured by ETDRS letter score from baseline (SD) Observed values at week 48: n=277 for HDq12; n=149 for HDq16; n=150 for 2q8 8.8 7.9
LS mean (SE) change from baseline Estimate based on the
MMRM model, was computed for the differences of HDq12 minus 2q8 and HDq16 minus 2q8, respectively with two-sided 95% CIs 8.1 7.2
Difference in LS mean (95% CI) -0.6 (-2.3, 1.1) -1.4 (-3.3, 0.4)
Efficacy Outcomes at Week 96 Mean change in BCVA as measured by ETDRS letter score from baseline (SD) Observed values at week 96: n= 222 for HDq12; n=127 for HDq16; n=124 for 2q8 8.8 7.5
LS mean (SE) change from baseline 8.2 6.6 7.7 Difference in LS
mean (95% CI), A non-inferiority margin was not available for week 96 0.5 (-1.6, 2.5) -1.1 (-3.3, 1.1) Efficacy results in all subgroups (e.g., age, gender, geographic region, ethnicity, race, baseline, BCVA, baseline CRT and prior DME treatment) were consistent with those in the overall population. Figure 9 : Mean Change from Baseline in BCVA as measured by ETDRS Letter Score by Visits through Week 96 (Observed Cases) Figure 9
Diabetic Retinopathy (DR) Efficacy and safety data of
EYLEA HD in diabetic retinopathy (DR) are derived from the PHOTON study. In the PHOTON study, a key efficacy outcome was the change in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (ETDRS-DRSS). Each EYLEA HD group was compared to the 2q8 group using a non-inferiority margin of 10%. The ETDRS-DRSS score was assessed at baseline and approximately every 3 months thereafter for the duration of the study . Baseline ETDRS-DRSS scores were generally balanced across treatment groups. 1.5% of total EYLEA HD treated patients who met protocol-defined criteria to be treated every 8 weeks did not maintain a response with every 8 weeks dosing after successful response to the 3 initial monthly doses. Results from the analysis of ETDRS-DRSS scores at weeks 48 and 96 in the PHOTON study are shown in Table 5 below: Table 5: Proportion of Patients Who Achieved a ≥2-Step Improvement from Baseline in the ETDRS-DRSS Score at Weeks 48 and 96 (Full Analysis Set) in PHOTON Efficacy Outcomes EYLEA HDq12 EYLEA HDq16 EYLEA 2q8 Missing or non-gradable post-baseline ETDRS-DRSS values were imputed using the last gradable ETDRS-DRSS values.
Patients were considered as non-responders if all post-baseline measurements were missing or non-gradable. Missing or ungradable baseline was not included in the denominator. Full Analysis Set FAS includes all randomized patients who received at least 1 dose of study medication N=328 N=163 N=167 Efficacy Outcomes at Week 48 Proportion of patients with a ≥2-step improvement on ETDRS-DRSS from Baseline (%) Last observation carried forward 29% 20% 27% Difference Difference with confidence interval (CI) was calculated using Mantel-Haenszel weighting scheme (%) (95% CI) 2% (-6.6, 10.6) -8% (-16.9, 1.8) Efficacy Outcomes at Week 96 Proportion of patients with a ≥2-step improvement on ETDRS-DRSS from Baseline (%) 34% 22% 31% Difference (%) (95% CI), A non-inferiority margin was not available for week 96 2.6% (-6.2, 11.5) -9.3% (-19.0, 0.3) The EYLEA HDq16 did not meet the non-inferiority criteria for the proportion of patients with a ≥2-step improvement on ETDRS-DRSS and is not considered clinically equivalent to EYLEA administered every 8 weeks.
Results of the subgroups (e.g., age, gender, geographic region, race, ethnicity, baseline BCVA, baseline CRT and prior DME treatment) on the proportion of patients who achieved a ≥2-step improvement on the ETDRS-DRSS from baseline to week 96 were, in general, consistent with those in the overall population.
Macular Edema Following Retinal Vein Occlusion (RVO)
The safety and efficacy of EYLEA HD was assessed in a randomized, multi-center, double-masked, active-controlled study (QUASAR) in patients with treatment naïve macular edema secondary to RVO. A total of 892 patients (425 with CRVO/HRVO and 467 with BRVO) were treated and analyzed for efficacy (591 with EYLEA HD). Patients were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: 1) EYLEA HD administered every 8 weeks, following 3 initial monthly doses (HDq8/3); 2) EYLEA HD administered every 8 weeks, following 5 initial monthly doses (HDq8/5); 3) EYLEA 2 mg administered every 4 weeks (2q4). Dosing intervals could be shortened or extended by 4-week increments based on protocol-defined visual and anatomic criteria. Intervals could be shortened beginning at week 16 for the HDq8/3 group, at week 24 for the HDq8/5 group and, if previously extended, at week 40 for the 2q4 group; intervals could be extended beginning at week 32 for the HDq8/3 and 2q4 groups and at week 40 for the HDq8/5 group. Patient ages ranged from 23 to 95 years with a mean of 65.9 years.
At baseline, mean visual acuity was approximately 55 letters (range: 18 to 74 letters). The primary efficacy endpoint was the change from baseline in BCVA at week 36 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. Both EYLEA HD groups were shown to be non-inferior and clinically equivalent to EYLEA with respect to the change in BCVA score at week 36 using the pre-specified non-inferiority margin of 4 letters. 9.1% of total EYLEA HD treated patients met protocol-defined criteria to be treated every 4 weeks. Detailed results from the analysis of the QUASAR study are shown in Table 6 and Figure 10 below.
Efficacy results in all subgroups (e.g., age, gender, geographic region, ethnicity, race, baseline BCVA and RVO subtype) were generally consistent with those in the overall population. Table 6: Efficacy Outcomes (Full Analysis Set) in QUASAR Study Efficacy Outcomes EYLEA HDq8/3 EYLEA HDq8/5 EYLEA 2q4 Full Analysis Set Full Analysis Set (FAS) includes all randomized patients who received at least 1 dose of study medication N=293 N=298 N=301 BCVA = Best Corrected Visual Acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; SD = Standard Deviation; LS = Least Square; SE = Standard Error; CI = Confidence Interval; MMRM = Mixed Model for Repeated Measurements Mean change in BCVA as measured by ETDRS letter score from baseline (SD) at week 36 Observed values at week 36: n=260 for HDq8/3; n=248 for HDq8/5; n=264 for 2q4 17.0 19.1
LS mean (SE) change from baseline Estimate based on the
MMRM model, was computed for the differences of HDq8/3 minus 2q4 and HDq8/5 minus 2q4, respectively, with two-sided 95% CIs 17.0 17.9
Difference in LS mean (95% CI) -0.1 (-2.0, 1.9) 0.8 (-1.1, 2.7)
Figure 10: Mean Change from Baseline in BCVA as measured by ETDRS Letter Score by Visits through Week 36 (Observed Cases) Figure 10
Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.
Ready to save on Eylea Hd?
Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.
Compare Eylea Hd Prices